Effectiveness and Safety of Nivolumab in Participants That Have Head and Neck Cancer That Has Come Back or Has Spread
NCT03569436 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 262
Last updated 2022-02-10
Summary
Non-interventional study in Japan of participants with HNC recurring or that has spread and who are treated with nivolumab
Conditions
- Cancer of Head and Neck
- Cancer of the Head
- Cancer of the Neck
Sponsors & Collaborators
-
Ono Pharma USA Inc
collaborator INDUSTRY - lead INDUSTRY
Principal Investigators
-
Bristol-Myers Squibb · Bristol-Myers Squibb
Eligibility
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2018-02-14
- Primary Completion
- 2020-06-26
- Completion
- 2020-06-26
Countries
- Japan
Study Locations
More Related Trials
-
Nivolumab in Recurrent and/or Metastatic SCCHN
NCT03226756 ·Status: COMPLETED ·Phase: PHASE2
-
Nimotuzumab Combined With Neoadjuvant Chemotherapy in the Treatment of Resectable LA HNSCC
NCT05351762 ·Status: UNKNOWN ·Phase: PHASE2
-
Predictive Biomarkers for Response to Nivolumab in Head and Neck Squamous Cell Carcinoma
NCT03652142 ·Status: UNKNOWN
-
Cetuximab & Nivolumab in Patients With Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma
NCT03370276 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Nivolumab and BMS986205 in Treating Patients With Stage II-IV Squamous Cell Cancer of the Head and Neck
NCT03854032 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Study of Nivolumab in Combination With Ipilimumab Compared to the Standard of Care (Extreme Regimen) as First Line Treatment in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
NCT02741570 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of Nivolumab in Participants With Squamous Cell Carcinoma of the Head & Neck (SCCHN) - Patient Reported Outcomes (PRO)
NCT05068609 ·Status: COMPLETED
-
Pembrolizumab Plus Olaparib in Patients With Recurrent Cervical Cancer
NCT04641728 ·Status: UNKNOWN ·Phase: PHASE2
-
Study of Chemo-Immunotherapy in Head and Neck Cancer Patients
NCT01149902 ·Status: UNKNOWN ·Phase: PHASE1
-
Safety Testing of Adding Nivolumab to Chemotherapy in Patients With Intermediate and High-Risk Local-Regionally Advanced Head and Neck Cancer
NCT02764593 ·Status: COMPLETED ·Phase: PHASE1
-
Rollover Study of Weekly Paclitaxel (BMS-181339) in Patients With Head and Neck Cancer
NCT00971867 ·Status: COMPLETED ·Phase: PHASE2
-
Study of GSK3359609 With Pembrolizumab and 5-fluorouracil (5-FU)-Platinum Chemotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
NCT04428333 ·Status: TERMINATED ·Phase: PHASE3
-
Study of Pharmacokinetic, Safety, Immunogenicity and Efficacy of CMAB819 and Nivolumab in R/M HNSCC
NCT04659369 ·Status: TERMINATED ·Phase: PHASE1
-
Phase II Multi-centered Study of Perioperative Ivonescimab Versus Pembrolizumab Combined with Standard of Care (SOC) in Patients with Resectable, Locally Advanced Head and Neck Squamous Cell Carcinoma
NCT06814067 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Assessment of Efficacy and Safety of Monalizumab Plus Cetuximab Compared to Placebo Plus Cetuximab in Recurrent or Metastatic Head and Neck Cancer
NCT04590963 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
A Study for Identification of Immune Determinants for Response to Nivolumab in Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma
NCT04603248 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Nivolumab Plus Gemcitabine in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma-HN17-11
NCT06440187 ·Status: COMPLETED ·Phase: PHASE2
-
Trilaciclib in Preventing Hematopoietic Suppression in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
NCT06714266 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Study of GSK3359609 and Pembrolizumab in Programmed Death Receptor 1-ligand 1 (PD-L1) Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
NCT04128696 ·Status: TERMINATED ·Phase: PHASE3
-
A Study of Nimotuzumab Plus Adebrelimab With Chemotherapy in Cisplatin-Ineligible Patients With Head And Neck Squamous Cell Carcinoma
NCT07105592 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Abemaciclib + Nivolumab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed or Recurred Within Six Months After Platinum-based Chemotherapy
NCT03655444 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Real-world Analysis on the Efficacy and Safety of Neoadjuvant Therapy for Head and Neck Squamous Cell Carcinoma （neoHNSCC）
NCT06011993 ·Status: UNKNOWN
-
Study of Nivolumab in Combination With Ipilimumab Versus Nivolumab in Combination With Ipilimumab Placebo in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
NCT02823574 ·Status: COMPLETED ·Phase: PHASE2
-
Adjuvant Nivolumab After Salvage Resection in Head and Neck Cancer Patients Previously Treated With Definitive Therapy
NCT03355560 ·Status: COMPLETED ·Phase: PHASE2
-
A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC)
NCT06064097 ·Status: RECRUITING ·Phase: PHASE2